EGFR and non-small cell lung carcinoma: Kanda et al. conducted a prospective phase II trial of gefitinib with intermittent introduction of other chemotherapeutic agents in patients with advanced NSCLC harboring EGFR mutations [13]. The study design involved the introduction of three cycles of cisplatin and docetaxel after eight weeks of gefitinib administration, followed by retreatment with gefitinib; the reported median PFS duration of 19.5 months and median OS duration of 48.0 months suggest that the treatment approach prevented the development of acquired resistance to EGFR-TKIs.